Want to see NUVB full AI Analyst Report?
NUVB Stock Chart & Stats
$7.10
-$0.07(-1.08%)
At close: 4:00 PM EDT
$7.10
-$0.07(-1.08%)
Day’s Range― - ―
52-Week Range$3.66 - $9.75
Previous CloseN/A
Volume6.14M
Average Volume (3M)5.26M
Market Cap
$1.58B
Enterprise Value$1.74B
Total Cash (Recent Filing)$660.96M
Total Debt (Recent Filing)$252.14M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
Nov 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding351,123,230
10 Day Avg. Volume5,817,932
30 Day Avg. Volume5,255,251
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)10.01
Price to Sales (P/S)48.65
P/FCF Ratio-17.61
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue10.22
Enterprise Value/Gross Profit10.88
Enterprise Value/Ebitda-13.67
Forecast
1Y Price Target
$14.57Price Target Upside105.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.4
Revenue Forecast (FY)$196.06M
Bulls Say, Bears Say
Bulls Say
IBTROZI Growth And Market LeadershipIBTROZI combines strong quarter-over-quarter revenue growth with leading first-line positioning in ROS1-positive lung cancer. A growing treated market and increasing first-line adoption can support durable revenue expansion as the patient base accumulates over multiple quarters.
Differentiated Clinical ProfileHigh response rates and prolonged duration of response and progression-free survival provide meaningful clinical differentiation for IBTROZI. Durable outcomes can reinforce physician and patient adoption, support treatment persistence, and strengthen the product’s competitive position in oncology.
Strong Liquidity And Low LeverageThe substantial liquidity position and modest leverage give Nuvation financial flexibility to fund commercialization and clinical programs without immediate dependence on operating cash generation. This extends execution capacity while reducing balance-sheet pressure during development and launch activities.
Bears Say
Persistent Losses And Cash BurnNuvation remains far from profitability despite revenue scaling, with large net losses and negative free cash flow showing that the current business has not yet funded its operations internally. Continued cash consumption can increase financing needs and constrain strategic flexibility over time.
High Costs And Gross-to-net PressureHeavy R&D and commercialization spending absorbs a substantial portion of revenue, while gross-to-net deductions reduce the amount retained from product sales. Unless revenue growth outpaces these recurring costs, margin conversion and the path to sustainable profitability may remain pressured.
Long And Uncertain Clinical TimelinesImportant safusidenib value inflection points are several years away, delaying potential regulatory and commercial benefits. Reliance on lengthy trials and exploratory or unvalidated endpoints also increases execution and regulatory uncertainty before those programs can contribute materially.
Nuvation Bio News
NUVB FAQ
What was Nuvation Bio’s price range in the past 12 months?
Nuvation Bio lowest stock price was $3.66 and its highest was $9.75 in the past 12 months.
What is Nuvation Bio’s market cap?
Nuvation Bio’s market cap is $1.58B.
When is Nuvation Bio’s upcoming earnings report date?
Nuvation Bio’s upcoming earnings report date is Nov 11, 2026 which is in 21 days.
How were Nuvation Bio’s earnings last quarter?
Nuvation Bio released its earnings results on Aug 06, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$0.038.
Is Nuvation Bio overvalued?
According to Wall Street analysts Nuvation Bio’s price is currently Undervalued.
Does Nuvation Bio pay dividends?
Nuvation Bio does not currently pay dividends.
What is Nuvation Bio’s EPS estimate?
Nuvation Bio’s EPS estimate is -0.12.
How many shares outstanding does Nuvation Bio have?
Nuvation Bio has 351,123,230 shares outstanding.
What happened to Nuvation Bio’s price movement after its last earnings report?
Nuvation Bio reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went down -4.082%.
Which hedge fund is a major shareholder of Nuvation Bio?
Currently, no hedge funds are holding shares in NUVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nuvation Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.57 (105.23% Upside)
$14.57 (105.23% Upside)
Blogger Sentiment
Bullish
NUVB Sentiment 87%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 138.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.91%
12-Months-Change
Fundamentals
Return on Equity
-49.73%
Trailing 12-Months
Asset Growth
15.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nuvation Bio
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
NUVB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive commercial and clinical trajectory: IBTROZI is demonstrating strong revenue growth, clear market leadership in first-line ROS1, exceptional clinical durability and favorable patient-reported outcomes, while safusidenib shows encouraging long-term activity and an expanded development plan. The company further strengthened its balance sheet via a well‑subscribed convertible note offering. Key near-term challenges include elevated operating expenses, gross-to-net pressure, community testing and prescribing inertia, and multi‑year timelines for Phase III readouts. Competitive entrants and dilution risk exist but were framed as manageable. On balance, the highlights (robust revenue growth, market share leadership, best-in-class clinical data, strong cash position and program expansion) materially outweigh the lowlights.View all NUVB earnings summariesNUVB Stock 12 Month Forecast
Average Price Target
$14.57
▲(105.23% Upside)
Technical Analysis
Kura Oncology
―
Syndax Pharmaceuticals
―
Zymeworks
―
Nurix Therapeutics
―
Olema Pharmaceuticals
―
Ownership Overview
24.64% Insiders
15.63% Mutual Funds
0.35% Other Institutional Investors
47.81% Public Companies and Individual Investors